The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib
Official Title: Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib.
Study ID: NCT02713763
Brief Summary: The therapeutic goals in the management of pancreatic neuroendocrine tumors (pNET) are the control of symptoms and tumor growth control in order to improve patient survival. In recent years, data from two phase III studies with targeted therapies, sunitinib and everolimus, have broadened the possibilities for treatment of patients with neuroendocrine tumors of the pancreas. Unfortunately, patients progress and development of new active drugs and evaluating the best treatment approach is decisive. Given the lack of data comparing the activity of different treatment strategies, final decisions are based on medical experience and consensus of experts. In this context, different questions are still unanswered, as which is the best sequence of treatment and if all patients can benefit from all available drugs. Neuroendocrine pancreatic tumors are highly vascularized tumors in which cells may be dependent on this pathway for growth throughout the entire history of the tumor and in which inhibition of this pathway is crucial. On the other hand, this aspect has not been endorsed by the population of patients with pNET who have previously failed treatment with sunitinib. In this scenario the investigators will assess retreatment with sunitinib to evaluate the activity of this drug in the context of therapeutic rescue in patients with metastatic pNET.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
Hospital Universitario Valle de Hebrón, Barcelona, , Spain
Hospital Reina Sofía, Córdoba, , Spain
Hospital Universitario Donostia, Donostia/San Sebastián, , Spain
Hospital Ramón y Cajal, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital General Universitario J.M. Morales Meseguer, Murcia, , Spain
Complejo Hospitalario Regional Virgen Del Rocío, Sevilla, , Spain
Instituto Valenciano de Oncología, Valencia, , Spain
Name: Enrique Grande
Affiliation: MD Anderson Cancer Center MADRID
Role: PRINCIPAL_INVESTIGATOR